These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
608 related articles for article (PubMed ID: 37200978)
1. The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease. Finney AC; Das S; Kumar D; McKinney MP; Cai B; Yurdagul A; Rom O Front Cardiovasc Med; 2023; 10():1116861. PubMed ID: 37200978 [TBL] [Abstract][Full Text] [Related]
2. Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease. Park JH; Koo BK; Kim W; Kim WH; Hepatol Int; 2021 Oct; 15(5):1148-1159. PubMed ID: 34081289 [TBL] [Abstract][Full Text] [Related]
3. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Negi CK; Babica P; Bajard L; Bienertova-Vasku J; Tarantino G Metabolism; 2022 Jan; 126():154925. PubMed ID: 34740573 [TBL] [Abstract][Full Text] [Related]
4. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Soejima Y; Fukusato T World J Gastroenterol; 2012 May; 18(19):2300-8. PubMed ID: 22654421 [TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic Fatty Liver Disease as an Emerging Risk Factor and Potential Intervention Target for Atherosclerotic Cardiovascular Diseases. Zhang D; Mi Z; Peng J; Yang T; Han Y; Zhai Y; Song C; Teng X; Sun W; Guo J; Bilonda KP J Cardiovasc Pharmacol; 2023 May; 81(5):327-335. PubMed ID: 36917556 [TBL] [Abstract][Full Text] [Related]
6. Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How? Choudhary NS; Duseja A J Clin Exp Hepatol; 2019; 9(4):506-514. PubMed ID: 31516267 [TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH). Ota T Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745 [TBL] [Abstract][Full Text] [Related]
8. New drugs for NAFLD: lessons from basic models to the clinic. Reimer KC; Wree A; Roderburg C; Tacke F Hepatol Int; 2020 Jan; 14(1):8-23. PubMed ID: 31802390 [TBL] [Abstract][Full Text] [Related]
9. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE. Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197 [No Abstract] [Full Text] [Related]